The vaccine against the malaria, developed by Blog about healthcompany GlaxoSmithKline, has been tested on children aged till one year. Results of clinical tests have appeared encouraging: the vaccine reduced risk of disease by a malaria on 65 % and did not cause serious by-effects, informs magazine Lancet. Scientists from Barcelonian universityFresh health news conducted vaccine tests under name Mosquirix in Medical research centre Maniki. 214 children have been included In research. To half from them three times - at the age of 10, 14 and 18 weeks the experimental vaccine from a malaria-was entered. To other half under the same scheme the vaccine from a hepatitis of Century was entered The estimation of efficiency of bacterination was spent after three months after introduction of last dose of a preparation. It was found out, that in both groups frequency of by-effects was approximately identical. The serious by-effects bound to introduction Mosquirix, it was revealed not. During too time in blood of children antibodies against a malarial plasmodium were defined. Health information During observations the malaria has arisen at 22 children receiving Mosquirix, and 46 - receiving a vaccine from hepatitis B.All about Health Thus, triple introduction of a vaccine against a malaria Healthy Newsreduced risk of development of disease on 65 %, the principal of research Pedro Alonso (Pedro Alonso) has informed.